An Open label Phase II//proof of concept-study to demonstrate if percutaneous application of
LTX-109 in a gel vehicle is a safe treatment of Hidradenitis suppurativa and to identify
clinical response to intervention, as well to identify if covariates such as age, disease
duration, smoking state and BMI influence patient reported measures.